Business
Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology
Technology invented and developed at Cleveland Clinic SAN JOSE, Calif., March 12, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"Technology invented and developed at Cleveland Clinic\n\n\nSAN JOSE, Calif., March 12, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued and published the first European patent for its novel ovarian cancer vaccine technology. This technology was invented and developed at Cleveland Clinic and Anixa is the worldwide licensee. \n\n \n \n \n \n \n \n\n \nThe patent is titled, \"Ovarian Cancer Vaccines,\" and the inventors are Drs. Vincent K. Tuohy, Suparna Mazumder, and Justin M. Johnson, all of Cleveland Clinic.\nDr. Amit Kumar, President and CEO of Anixa Biosciences, stated, \"We are pleased that the European Patent Office (EPO) has issued this patent. This ovarian cancer vaccine has the potential to eliminate one of the deadliest malignancies in women. Ovarian cancer is often diagnosed after it has reached Stage 3 or 4, and when it is difficult to effectively treat. Five-year survival statistics for ovarian cancer are poor, so if this vaccine is able to eliminate the onset of ovarian cancer, the impact for women and for our healthcare system will be tremendous.\"\n\"The ovarian cancer vaccine targets a protein (the Extracellular Domain of the Anti-Mullerian Hormone Receptor 2, AMHR2-ED) that is expressed only in the ovaries and only in pre-menopausal women. After menopause, the target protein disappears and is only seen again when ovarian cancer cells arise. Our vaccine targets the AMHR2-ED and trains the immune system to destroy these cancer cells as they arise,\" said Dr. Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. \"We are looking forward to our continued alliance with Anixa Biosciences to further develop this technology.\" \nAbout Anixa Biosciences, Inc.Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast...